AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of July 2018. The Company, a foreign private issuer based in Lausanne, Switzerland, reported the closing of its second subscription rights offering on July 31, 2018.
Key Financial Metrics
- Capital Raised (Second Offering): Gross proceeds of $17.6 million from the issuance of 1,500,000 common shares at $11.75 per share.
- Capital Raised (First Offering): Gross proceeds of $99.9 million from 8,500,000 common shares issued on July 23, 2018.
- Total Aggregate Proceeds: $117.5 million from all three offerings referenced in the filing.
- Share Price: $11.75 per common share.
- Operating Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the successful completion of a capital raise. The Company closed a second subscription rights offering, increasing its equity capital by $17.6 million. This follows a larger offering closed one week prior, resulting in a total capital infusion of $117.5 million across the series of offerings.
Outlook, Risks, and Management Commentary
The filing confirms the validity of the shares issued through an opinion from Swiss counsel, Vischer AG. The offering was conducted pursuant to an effective registration statement on Form F-3. The text does not contain specific management commentary on future business outlook, operational risks, contingencies, or unusual items beyond the execution of the capital raise.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-offering to assess dilution impact.
- Confirm the specific use of the $117.5 million in aggregate proceeds (e.g., clinical trials, operations).
- Review the Company's cash position and burn rate to determine runway extension provided by this capital.
- Check for any subsequent filings regarding the performance of the newly issued shares.